Asmanex Twisthaler is a drug owned by Organon Llc. It is protected by 21 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 17, 2018. Details of Asmanex Twisthaler's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US8173172 (Pediatric) | Preparation of powder agglomerates |
Sep, 2018
(6 years ago) |
Expired
|
|
US6503537 (Pediatric) | Preparation of powder agglomerates |
Sep, 2018
(6 years ago) |
Expired
|
| US6503537 | Preparation of powder agglomerates |
Mar, 2018
(6 years ago) |
Expired
|
| US8173172 | Preparation of powder agglomerates |
Mar, 2018
(6 years ago) |
Expired
|
|
US6240918 (Pediatric) | Powdered medication inhaler |
Aug, 2017
(7 years ago) |
Expired
|
| US6240918 | Powdered medication inhaler |
Feb, 2017
(7 years ago) |
Expired
|
|
US5829434 (Pediatric) | Inhaler for powdered medications |
May, 2016
(8 years ago) |
Expired
|
| US5829434 | Inhaler for powdered medications |
Nov, 2015
(9 years ago) |
Expired
|
|
US5687710 (Pediatric) | Inhaler for powdered medications having spiral deagglomeration chamber |
May, 2015
(9 years ago) |
Expired
|
| US5687710 | Inhaler for powdered medications having spiral deagglomeration chamber |
Nov, 2014
(10 years ago) |
Expired
|
|
US6365581 (Pediatric) | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
|
US6949532 (Pediatric) | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
|
US6677322 (Pediatric) | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
|
US6057307 (Pediatric) | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
|
US5889015 (Pediatric) | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
| US6949532 | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
| US6677322 | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
| US6057307 | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
| US6365581 | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
| US5889015 | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
|
US5394868 (Pediatric) | Inhalation device for powdered medicaments |
Dec, 2012
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Asmanex Twisthaler's patents.
Latest Legal Activities on Asmanex Twisthaler's Patents
Given below is the list of recent legal activities going on the following patents of Asmanex Twisthaler.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Jun, 2020 | US8173172 |
| Maintenance Fee Reminder Mailed Critical | 30 Dec, 2019 | US8173172 |
| Expire Patent Critical | 23 Oct, 2017 | US6949532 |
| Expire Patent Critical | 05 Feb, 2016 | US6677322 |
| Patent Issue Date Used in PTA Calculation Critical | 08 May, 2012 | US8173172 |
| Recordation of Patent Grant Mailed Critical | 08 May, 2012 | US8173172 |
| Issue Notification Mailed Critical | 18 Apr, 2012 | US8173172 |
| Dispatch to FDC | 13 Apr, 2012 | US8173172 |
| Application Is Considered Ready for Issue Critical | 29 Mar, 2012 | US8173172 |
| Dispatch to FDC | 29 Mar, 2012 | US8173172 |
US patents provide insights into the exclusivity only within the United States, but Asmanex Twisthaler is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Asmanex Twisthaler's family patents as well as insights into ongoing legal events on those patents.
Asmanex Twisthaler's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Asmanex Twisthaler's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 17, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Asmanex Twisthaler Generic API suppliers:
Mometasone Furoate is the generic name for the brand Asmanex Twisthaler. 14 different companies have already filed for the generic of Asmanex Twisthaler, with Cosette having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Asmanex Twisthaler's generic
Alternative Brands for Asmanex Twisthaler
Asmanex Twisthaler which is used for managing and controlling symptoms of asthma., has several other brand drugs in the same treatment category and using the same active ingredient (Mometasone Furoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Organon Llc |
| |||||
| Teva Pharm |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Mometasone Furoate. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Mometasone Furoate, Asmanex Twisthaler's active ingredient. Check the complete list of approved generic manufacturers for Asmanex Twisthaler
About Asmanex Twisthaler
Asmanex Twisthaler is a drug owned by Organon Llc. It is used for managing and controlling symptoms of asthma. Asmanex Twisthaler uses Mometasone Furoate as an active ingredient. Asmanex Twisthaler was launched by Organon Llc in 2008.
Approval Date:
Asmanex Twisthaler was approved by FDA for market use on 01 February, 2008.
Active Ingredient:
Asmanex Twisthaler uses Mometasone Furoate as the active ingredient. Check out other Drugs and Companies using Mometasone Furoate ingredient
Treatment:
Asmanex Twisthaler is used for managing and controlling symptoms of asthma.
Dosage:
Asmanex Twisthaler is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.22MG/INH | POWDER | Prescription | INHALATION |
| 0.11MG/INH | POWDER | Prescription | INHALATION |